Table 1.
Demographic and Treatment Characteristics of Eligible Participants in This Study
| CCSS Original Cohort (n = 3,572) | CCSS Expansion Cohort (n = 1,889) | SJLIFE (n = 2,534) | |
|---|---|---|---|
| Sex | |||
| Female | 1,876 (52.5) | 994 (52.6) | 1,198 (47.3) |
| Male | 1,696 (47.5) | 895 (47.4) | 1,336 (52.7) |
| Smoker | |||
| Never | 2,841 (79.5) | 1,368 (72.4) | 1,656 (65.4) |
| Current/past | 731 (20.5) | 521 (27.6) | 878 (34.6) |
| Hypertension | |||
| No | 2,782 (77.9) | 1,729 (91.5) | 1,806 (71.3) |
| Yes | 790 (22.1) | 160 (8.5) | 728 (28.7) |
| Abdominal radiation | |||
| No | 2,661 (74.5) | 1,570 (83.1) | 2,042 (80.6) |
| Yes | 911 (25.5) | 319 (16.9) | 492 (19.4) |
| Total body irradiation | |||
| No | 3,559 (99.6) | 1,875 (99.3) | 2,531 (99.9) |
| Yes | 13 (0.4) | 14 (0.7) | 3 (0.1) |
| Hypothalamic-pituitary axis radiation | |||
| No | 1,278 (35.8) | 1,151 (60.9) | 1,146 (45.2) |
| Yes | 2,294 (64.2) | 738 (39.1) | 1,388 (54.8) |
| Nephrectomy | |||
| No | 3,229 (90.4) | 1,736 (91.9) | 2,369 (93.5) |
| Yes | 343 (9.6) | 153 (8.1) | 165 (6.5) |
| Alkylating agents | |||
| No | 1,816 (50.8) | 849 (44.9) | 1,068 (42.1) |
| Yes | 1,756 (49.2) | 1,040 (55.1) | 1,466 (57.9) |
| Heavy metals | |||
| No | 3,406 (95.4) | 1,577 (83.5) | 2,231 (88.0) |
| Yes | 166 (4.6) | 312 (16.5) | 303 (12.0) |
| Age at cancer diagnosis, yrs | |||
| Median (IQR) | 7.7 (10.5) | 8.9 (9.9) | 7.7 (10.2) |
| Age at last contact, yrs | |||
| Median (IQR) | 41.5 (12.4) | 30.1 (8.5) | 35.5 (15.3) |
| Body mass index, kg/m2 | |||
| Median (IQR) | 22.8 (5.5) | 24.8 (6.9) | 26.4 (8.9) |
Values are n (%), unless otherwise indicated. All the survivors are of European ancestry.
CCSS = Childhood Cancer Survivor Study; IQR = interquartile range; SJLIFE = The St. Jude Lifetime Cohort.